

MUNICIPAL YEAR 2017/18

Meeting Title:
Health and Wellbeing Board
Date: 19th April 2017

Agenda Item:

**Subject: Enfield Pharmaceutical
Needs Assessment**

Contact officer: Miho Yoshizaki
Telephone number: 0208 379 5351
Email address:
miho.yoshizaki@enfield.gov.uk

**Report approved by:
Tessa Lindfield
Director of Public Health**

1. EXECUTIVE SUMMARY

The Health and Wellbeing Board (HWB) is responsible for preparing the Pharmaceutical Needs Assessment (PNA) of the borough, which will inform market entry and commissioning of pharmaceutical services. The next Enfield PNA is due April 2018.

This report outlines the proposed process of Enfield PNA and seeks HWB's approval to progress this programme.

2. RECOMMENDATIONS

- The Board is asked to note the PNA responsibilities and proposed time frame.
- The Board is asked to endorse the proposal to delegate authority to the PNA steering group in preparing the Enfield PNA.
- The Board is asked to endorse the proposed process for the Enfield Pharmaceutical Needs Assessment.

3. BACKGROUND

3.1 The National Health Service (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 (SI 2013 No. 349) set out the system for market entry to provide community pharmacy services.

3.2 Under the Regulations, Health and Wellbeing Boards are responsible for publishing a statement of the current and future needs for the pharmaceutical services for the population in its area, referred to as

Pharmaceutical Needs Assessment (PNA), every three years; and NHS England is responsible for considering applications and maintaining the pharmaceutical list.

- 3.3 The first PNA since the responsibility was transferred to the HWB was published in March 2015 and is available at [the Council website](#).
- 3.4 The next Enfield PNA is due for April 2018.
- 3.5 Although the National Health Service (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 (SI 2013 No. 349) is due for review by The Secretary of State (the first report due by the end of August 2017), there has not been any indication on significant changes to the PNA process. Given the time needed to address all the requirements for the PNA, Enfield's review process needs to be initiated.

4. REPORT

- 4.1 PNAs are used by NHS England as a basis to determine market entry to a pharmaceutical list. NHS England use the PNA to review whether any new applicant is able to meet a pharmaceutical need, as outlined in the relevant PNA, as well as to consider decisions to move or commission additional services from existing pharmacies.
- 4.2 PNAs can also be used to inform the commissioning of enhanced or locally commissioned services from pharmacies by NHS England, Local Authority, Clinical Commissioning Groups (CCG) and other local commissioners.
- 4.3 Below outlines the minimum requirement for the PNA;
 - A statement of the pharmaceutical services provided that are necessary to meet needs in the area;
 - A statement of the pharmaceutical services that have been identified by the HWB that are needed in the area, and are not provided (gaps in provision);
 - A statement of the other services which are provided, which are not needed, but which have secured improvements or better access to pharmaceutical services in the area;
 - A statement of the services that the HWB has identified as not being provided, but which would, if they were to be provided, secure improvements or better access to pharmaceutical services in the area;
 - A statement of other NHS services provided by a local authority, the NHS Commissioning Board (NHS England), a Clinical Commissioning Group (CCG) or an NHS Trust, which affect the needs for pharmaceutical services;
 - An explanation of how the assessment has been carried out (including how the consultation was carried out); and
 - A map of providers of pharmaceutical services

- Consultation. HWB must consult the bodies set out in Regulation 8 at least once during the process of developing PNA. The minimum consultation period required is 60 days.

Proposed process

- 4.4 As per the previous PNA, it is proposed that Enfield will commission analyses of unmet pharmaceutical needs, development of PNA framework and report production to external specialist consultant. This will ensure Enfield's PNA is delivered to high standard meeting all legal requirements, while minimising the cost. The financial envelope for this programme is £25,000 - £30,000 and will be funded by Public Health.
- 4.5 Public Health team will also provide resources to manage the overall project and provide quantitative analyses on health needs of the borough, while the Council's corporate hub will provide support in conducting qualitative information gathering and consultation.
- 4.6 The PNA steering group will be set up to provide strategic direction of the process. The steering group will be responsible for ensuring the accuracy of the PNA and ensure that PNA is fit for purpose.

Proposed PNA timeline

- 4.7 Proposed timeline for the PNA is outlined below:

Stage	Dates	Key actions
Set up	April – June 2017	<ul style="list-style-type: none"> • HWB paper to outline PNA responsibilities. Delegated authority to PNA steering group. • Setting up PNA steering group and first meeting. • Produce project plan and secure resources. • Agree work stream plans and timelines.
Information finding	June – July 2017	<ul style="list-style-type: none"> • Collating necessary information including current pharmaceutical services in Enfield and health needs of the borough
Analyses	August – September 2017	<ul style="list-style-type: none"> • Analyses of pharmaceutical needs in Enfield • Identification and agreement to any potential gaps in pharmaceutical service provision • Any changes in legislation to be addressed during this process
Draft PNA production	September – October 2017	<ul style="list-style-type: none"> • Completing draft PNA for consultation • Presentation to HWB on progress and draft PNA
Consultation	November – December 2017	<ul style="list-style-type: none"> • Complete minimum 60 days of consultation
Final consideration	January – February 2017	<ul style="list-style-type: none"> • Analyses of consultation and amendments to PNA as appropriate • Agreement on final PNA
HWB approval	February – March 2017	<ul style="list-style-type: none"> • Health and Wellbeing Board presentation and approval
Publication	February – March 2017	<ul style="list-style-type: none"> • Following the HWB approval, publish the PNA

5. Recommendations

- 5.1 The Board is asked to note the PNA responsibilities and proposed time frame.
- 5.2 The Board is asked to endorse the proposal to delegate authority to the PNA steering group in preparing the Enfield PNA.
- 5.3 The Board is asked to endorse the proposed process for the Enfield Pharmaceutical Needs Assessment.